Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205629 | 0.94 | F10 (0.74) | F10 | |
| SCHEMBL5201704 | 0.94 | F10 (0.74) | F10 | |
| SCHEMBL14593815 | 0.90 | F10 (0.76) | F10 | |
| SCHEMBL5204047 | 0.88 | F10 (0.56) | F10HDAC3HDAC2 | |
| SCHEMBL5201703 | 0.88 | F10 (0.56) | F10 | |
| SCHEMBL5205064 | 0.87 | F10 (0.83) | F10 | |
| SCHEMBL5202862 | 0.86 | F10 (0.63) | F10HDAC3HDAC2CYP1A2CYP2C18 | |
| SCHEMBL5201432 | 0.86 | F10 (0.55) | F10HDAC3HDAC2KCNH2 | |
| SCHEMBL5387675 | 0.85 | F10 (0.88) | F10 | |
| SCHEMBL5369020 | 0.85 | MAPT (0.51) | F10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | F10 11/4885HDAC3 149/4885HDAC2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.